Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation.

Visit the Open Targets Platform which integrates public domain data to enable target identification and prioritisation, or the Open Targets Genetics Portal which identifies targets based on GWAS and functional genomics. We complement data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation. Check out our latest papers describing our experimental target identification approaches in oncology, neurodegeneration, and immunity and inflammation.


News

Open Targets releases a COVID-19 Target Prioritisation Tool

Wednesday 29 July 2020 | Cambridge, UK

Open Targets is excited to announce the release of our COVID-19 Target Prioritisation Tool, an interactive, open source web portal that integrates a number of key public datasets and publications to facilitate systematic exploration of host and viral targets as well as potential treatments for COVID-19.

To learn more about the tool, visit our blog.


Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.


Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Rapid publication

We are committed to rapid publication and making data, methods and results publicly available as soon as possible

Open collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data


Follow Us


Q&A with Eddie Cano-Gámez, winner of the 2020 Charles J. Epstein Trainee Award

Eddie Cano-Gamez | December 01, 2020

Open Targets Platform 20.11 released!

Andrew Hercules | November 26, 2020

We have a new release of the Open Targets Platform - 20.11 - which includes data updates from C...

In-GenIE-ous experiments to find causal variants from GWAS

Sarah Cooper | November 16, 2020

How we improved our clinical trial curation during the COVID-19 lockdown

Ellie McDonagh | November 11, 2020

With many of our lab-based colleagues unable to access their research labs, we set up special pro...

The importance of Autophagy in drug discovery

Thawfeek M Varusai | October 29, 2020

Cellular autophagy is known to be dysregulated in a range of human diseases, including cancer and...